Navigation Links
Avrio Appoints David L. Gelber to Director of Manufacturing
Date:6/29/2010

IRVINE, Calif., June 29 /PRNewswire/ -- Avrio Biopharmaceuticals, LLC, a premier pharmaceutical manufacturing and development organization announces the addition of David A. Gelber as the Director of Manufacturing. Mr. Gelber will be responsible for streamlining and enhancing Avrio's quality production systems and ensuring clients receive high quality service in a timely manner.

"We are excited to have David join Avrio. He is passionate about serving our customers and dedicated to operational excellence," said CEO and Founder, Dr. Assad J. Kazeminy. "David's experience and leadership skills exhibit our commitment to scientific excellence, leading-edge resources, and dependable customer care."

Mr. Gelber has over 25 years of experience with production and project management, and has demonstrated knowledge of all areas of aseptic pharmaceutical manufacturing. David has extensive experience serving as the manufacturing and operations head for both contract and commercial manufacturing operations.  His previous work experience includes serving as the Director of Operations for AAI Development Services, as well as holding a similar sales and management role for B. Braun Medical, Inc.

"David offers our clients solutions to their problems and peace of mind that we'll deliver as promised and we are confident that the future for Avrio is very promising," said Yvonne Verburgt, Vice President of Business Development and Marketing.

To learn more about how Avrio is growing to accommodate client needs, visit '/>"/>

SOURCE Avrio Biopharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Avrio Receives Drug Manufacturing License and Medical Device Manufacturing License from the California Food and Drug Branch
2. Yvonne Verburgt Joins the Avrio Executive Team as Vice President of Business Development and Marketing
3. Quark Pharmaceuticals Appoints New Chief Medical Officer
4. West Pharmaceutical Services, Inc. Appoints New Director
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Curemark Appoints Preeminent Pediatrics Gastroenterologist
7. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
10. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
11. NovaRx Appoints Industry Veteran as President and COO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... February 15, 2012 It has become common ... to be required to submit to random drug screens as ... this billable procedure is to prevent and reduce opioid associated ... the efficacy of drug testing people with chronic pain.   ...
... N.J., Feb. 15, 2012  Omthera Pharmaceuticals, Inc., a ... Jerry Wisler, President and Chief Executive Officer, will present ... Thursday, February 16, 2012 at 3:20 p.m. EST.  He ... on February 29, 2012 at 11:00 a.m. EST.  Both ...
Cached Medicine Technology:New Evidence Points to a "Profits Over Efficacy" Approach to Drug Testing 2Omthera Pharmaceuticals, Inc. to Present at Leerink Swann 2012 Global Healthcare Conference and Citi 2012 Global Healthcare Conference 2
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at Virginia ... blocking a particular molecule in metastatic breast cancer reduces ... of lung metastases. BRI scientists have found in models ... tumors by 60 - 80 percent and can keep ... The $1.8 million five-year grant comes from the National ...
(Date:4/17/2014)... presence of chronic inflammation in benign prostate tissue ... and this association was found even in those ... a study published in Cancer Epidemiology, Biomarkers ... Association for Cancer Research. , An analysis of ... the placebo arm of the Prostate Cancer Prevention ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2
... submit abstracts to present their research at the ... to molecular imaging and nuclear medicineJune 13-17, 2009, ... molecular imaging is vital and state-of-the-art," said SNM ... society,s more than 17,000 molecular imaging and nuclear ...
... associated with an increased risk of fetal growth restriction ... bmj.com today. , Although some previous studies ... that any amount and type of caffeine intakefrom tea, ... as coffeeis linked with relatively slower fetal growth. ...
... Nov. 3 Pregis Corporation, a leading,international ... and specialty packaging solutions, will conduct an ... quarter results on Friday,November 14, 2008 at ... 800-591-6942;,International: 617-614-4909; Participant Passcode: 68623125. A replay ...
... QIAGEN N.V.,(Nasdaq: QGEN ) today announced the Webcast of ... at 9:30 a.m. EST on,Tuesday, November 11, and will include remarks ... Chief Financial Officer., What: Webcast ... 9:30 a.m. EST on November 11, Where: ...
... common correction techniques yield positive results, ROSEMONT, ... used to correct the condition known as clubfoot,have ... new study published,in the November 2008 issue of ... ). While both treatment strategies use different,approaches, each ...
... ANGELES, Nov. 3 World Champion athlete and ... debut as a member of the,California Governor,s Council ... speaking to the student body of NEW Academy ... and healthy lifestyles., (Photo: http://www.newscom.com/cgi-bin/prnh/20081103/AQM074 ), ...
Cached Medicine News:Health News:SNM to showcase the latest research in molecular imaging and nuclear medicine 2Health News:Consuming small amounts of caffeine when pregnant may affect the growth of an unborn child 2Health News:Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Third Quarter 2008 Financial Results Call Set for November 11 2Health News:Non-Surgical Clubfoot Treatments Bring High Level of Success 2Health News:Non-Surgical Clubfoot Treatments Bring High Level of Success 3Health News:Laila Ali Debuts as Member of California Governor's Council on Physical Fitness and Sports 2
... Sorvall DiscoveryTMM150 SE Micro-ultra centrifuge continues to ... sample processing, now with 1,048,000 x g ... rotor. DiscoveryTMM150SE processes sample sizes from ... small floor footprint, brushless direct drive, very ...
... and environmental safety are the ... K Ultracentrifuge from Beckman Coulter. ... centrifugation technology, the LE-80 K ... provide advanced capability for your ...
... Optima L-XP ultracentrifuge is designed to ... discovery process if research involves proteomics, ... sophisticated on-board computer, enhanced firmware, powerful ... touch screen, Optima L-XP delivers superior ...
... chemistry system brings versatility in a ... laboratory. A model of innovation and ... system features state-of-the-art Dimension testing technology, ... in a flexible. affordable, easy-to-use system ...
Medicine Products: